GlassScriptPhysician profile
Alexander Pendergrass
NPI 1982212841
$2,381.02
in general payments reported to CMS, 2019-2025
23 companies · $680 in 2025
The $680 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $231 · 2023: $463 · 2024: $832 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.40 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.25 | 2021-2025 | |
| Novo Nordisk INC | $332.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.18 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $175.51 | 2024-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $151.01 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.49 | 2022 | |
| Abbott Laboratories | $141.35 | 2021-2024 | Cardiomems, Gallant, Eterna |
| Inspire Medical Systems, INC. | $118.71 | 2023-2025 | Inspire |
| Lilly USA, LLC | $73.37 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $54.27 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $49.52 | 2023 | Xarelto, Spravato |
| Antares Pharma, INC. | $47.58 | 2024-2025 | Xyosted |
| Genentech USA, INC. | $42.59 | 2021 | |
| Amgen INC. | $33.55 | 2024 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.49 | 2024-2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $29.59 | 2022-2023 | |
| Astellas Pharma US INC | $23.08 | 2023 | Myrbetriq |
| Genzyme Corporation | $21.23 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.48 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $15.69 | 2024 | Qelbree, Xyosted |
| Janssen Biotech, INC. | $15.29 | 2025 | Tremfya |
| Biohaven Pharmaceuticals, INC. | $14.58 | 2021 | |
| Halozyme INC | $13.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Pendergrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.